Aurobindo Pharma's Q2 FY 2026-27 Quarterly Results

Result Summary

• Aurobindo Pharma Ltd reported a 10.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a growth of 24.1%.
• Its expenses for the quarter were up by 11.2% QoQ and 22.6% YoY.
• The net profit increased 8.9% QoQ and increased 32.5% YoY.
• The earnings per share (EPS) of Aurobindo Pharma Ltd stood at 19.57 during Q2 FY 2026-27.

Financial Statments for Q2 FY 2026-27

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aurobindo Pharma Ltd is an Indian pharmaceutical company that operates primarily in the healthcare sector, specializing in the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients. The company serves a wide range of therapeutic areas, including anti-retrovirals, cardiovascular, central nervous system, gastroenterology, and antibiotics. Aurobindo Pharma has a significant presence in both domestic and international markets, exporting a substantial portion of its products to over 150 countries. The company is known for its robust R&D capabilities and extensive manufacturing infrastructure. As of the last known update, the company has been focusing on expanding its portfolio through strategic acquisitions and product launches.

Revenue

During the second quarter of the fiscal year 2027 (Q2FY27), Aurobindo Pharma Ltd reported a total income of ₹10,431.51 crores. This represents a quarter-over-quarter (QoQ) increase of 10.8% from ₹9,414.58 crores in Q1FY27. The year-over-year (YoY) growth was 24.1% from ₹8,406.29 crores in Q2FY26. This growth in total income reflects an increase in the company's revenue-generating activities over both the previous quarter and the same quarter of the previous year. The substantial year-over-year growth suggests that the company achieved higher sales volumes or improved pricing strategies during this period.

Profitability

Aurobindo Pharma's Profit Before Tax (PBT) for Q2FY27 amounted to ₹1,690.61 crores, which is a 11.5% increase from Q1FY27's ₹1,516.63 crores and a 32.7% rise from ₹1,274.26 crores in Q2FY26. The company's tax expenses for the quarter were ₹563.83 crores, marking a 16.7% increase QoQ and a 31.8% increase YoY. Consequently, the Profit After Tax (PAT) was ₹1,123.84 crores, showing an 8.9% growth QoQ and a 32.5% increase YoY. These figures indicate that the company maintained a steady profitability trajectory, with significant improvements in both pre-tax and post-tax profit margins compared to previous periods.

Operating Metrics

For Q2FY27, Aurobindo Pharma reported an Earnings Per Share (EPS) of ₹19.57, which increased by 9.6% from ₹17.86 in Q1FY27 and by 33.9% from ₹14.61 in Q2FY26. The operating metrics reflect the company's ability to enhance shareholder value through improved earnings performance. The total expenses for the quarter were ₹8,740.90 crores, up by 11.2% QoQ from ₹7,857.77 crores and by 22.6% YoY from ₹7,132.03 crores. The rise in expenses was consistent with the revenue growth, indicating a scalable cost structure. The company maintained a robust operational performance, as evidenced by the alignment of expense growth with revenue increases, contributing to improved earnings per share.